Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PREDICT-TB

Financiado

Cerrado

Model-based preclinical development of anti-tuberculosis drug combinations

Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration... ver más

31/10/2017

GLAXOSMITHKLINE IN...

29M€

Presupuesto del proyecto: 29M€

Líder del proyecto

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO Investigacion y desarrollo de medicamentos entendiendo como tal el. conjunto de actividades consistentes en la investigacion cientifica

TRL 4-5 | 130K€

Fecha límite participación Sin fecha límite de participación.

Ver 18 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2017-10-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

18 Participantes

GLAXOSMITHKLINE INVESTIGACIO...

Lider

UC3M

N.D. | Participante

LSTM

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 65 meses Fecha Inicio: 2012-05-01
Fecha Fin: 2017-10-31

Líder del proyecto

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO Investigacion y desarrollo de medicamentos entendiendo como tal el. conjunto de actividades consistentes en la investigacion cientifica

TRL 4-5 | 130K€

Presupuesto del proyecto 29M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical systems which do not capture in vivo pharmacodynamics of heterogeneous states of M.tuberculosis.These systems are diverse and their predictive power for clinical trial outcomes is uncertain, escalating risks during development. To overcome these bottlenecks, PreDiCT-TB will take a comprehensive model based approach, synthesizing and integrating preclinical and clinical information. We will harness innovative technologies to develop an integrated set of predictive pre-clinical tools to facilitate selection of the best drug combinations and dosages for entry into optimized clinical studies. We will develop diverse existing and innovative experimental models of pharmacodynamics from extracellular MTB organisms, through to acute and chronic animal models in different species. We will enhance these systems using innovative single cell and functional imaging, novel mycobacteriological approaches and identification of biomarkers of lethality and sterilization. We will represent these critical data using multi-scale mathematical approaches incorporating PK-PD and disease models, supported by a translational data integration platform.The aim is an optimized decision pathway for combination regimens to progress to innovative early clinical trials. We will develop this modelling framework using a training set of reference compounds and subsequently update it with emerging data from new compounds. We believe that this comprehensive approach is the only way to overcome existing gaps in translation and create an effective and rapid drug development strategy for European researchers.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores